Login to Your Account



Other News To Note


Wednesday, January 11, 2012
• DFH Pharma Inc., of Gaithersburg, Md., is collaborating with the National Cancer Institute (NCI) to develop the next generation of HIV maturation inhibitor drugs. DFH has identified a series of second-generation maturation inhibitors with the broad antiviral activity profile necessary for HIV drug development. Under the agreement, NCI investigators will evaluate the activity of those compounds against HIV strains associated with reduced bevirimat activity.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription